Hot Investor Mandate 3: Venture Firm Seeks Immunology Assets Worldwide

11 Aug

A US-based venture firm that builds companies around early stage technologies is investing from a $400 million fund.  The firm is seeking to invest in therapeutic assets and is open to opportunites globally.

The firm is currently interested immunology assets that aim to treat infectious diseases (viral and bacterial), with a focus on assets related to immune priming or changing the immune system. Any therapeutic modality is of interest, including vaccines. The firm is interested in reviewing immunology assets at any stage of development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: